Condensed Consolidated Statements of Operations (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2012	Mar. 31, 2011
Revenues	$ 726	$ 369
Cost of revenues	22	238
Gross profit	704	131
Sales and marketing expenses	205	316
General and administrative expenses	1,000	794
Research and development costs	334	401
Operating Loss	(835)	(1,380)
Gain/(Loss) from change in fair value of hybrid financial instruments	(31,170)	2,471
Gain/(Loss)from change in fair value of derivative liability - warrants	(41,488)	1,782
Gain/(Loss) from change in fair value of derivative liability - Series C and D preferred stock and debentures	(89,649)	6,671
Interest expense related to convertible debt	(2,392)	(753)
Net Income (loss)	(165,534)	8,791
Dividends on convertible preferred stock	0	0
Net Income (loss) available to common shareholders	(165,534)	8,791
Comprehensive income (loss):
Net income (loss)	(165,534)	8,791
Other comprehensive loss - foreign currency translation adjustment	(8)	(9)
Comprehensive Income (loss)	$ (165,542)	$ 8,782
Net income (loss) per share, basic and diluted:
Basic (in dollars per share)	$ (0.25)	$ 0.20
Fully diluted (in dollars per share)	$ (0.25)	$ 0
Weighted average number of common shares:
Basic (in shares)	652,829,594	44,655,496
Fully diluted (in shares)	652,829,594	2,290,074,838